Handok held a symposium to present the mid-term trial results for Tenelia Tab., a diabetes treatment, at the Korean Diabetes Association’s spring conference on May 4.
The trial presented at the conference relates to an observational study conducted on 1,888 patients with type 2 diabetes at about 200 research institutes in Korea for 52 weeks.
The trial aimed to evaluate the safety and efficacy on the change in medication to Tenelia for patients, who failed to reach optimal blood sugar levels, HbA1c less than 7, despite talking DPP-4 inhibitor such as ciprofloxacin, cyproglitine, bilagliptin, linagliptin, saxagliptin, allogliptin and gemigliptin, for at least 12 weeks.
In the interim analysis of the study, patient’s HbA1c decreased by 0.44 percent statistically from baseline after 12 weeks of switching their treatment from the existing DPP-4 inhibitor to Tenelia . Also, the company confirmed additional blood glucose lowering effect along with decreases in fasting blood glucose, body weight, and BMI.
“Actively managing blood glucose levels at an early stage not only improve blood glucose levels in the future but also reduce the incidence of future diabetic complications,” Professor Kim Hye-jin from the department of endocrinology at Ajou University Hospital said. “Through this study, we were able to confirm that Tenelia can be an alternative treatment option for type 2 diabetes patients, who do not respond well to conventional DDP-4 inhibitors.”
Tenelia is a DPP-4 inhibitor that has recently been on the rise. Its inherent structural properties and long half-life of about 24 hours allow the drug to be effective for an extended period. Clinical studies have shown that seven out of 10 patients with type 2 diabetes reach their target blood glucose levels while being able to regulate their glucose levels with one pill a day tightly.